#1 - Cancer Genetics
NASDAQ:CGIX - See Stock Forecast- Stock Price:
- $0.19
- Market Cap:
- $792 thousand
- Consensus Rating:
- N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target:
- N/A
Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.
